Ask AI
ProCE Banner Activity

ARROS-1: Phase I/II Study of Zidesamtinib for Patients With Advanced ROS1+ NSCLC After Prior ROS1 TKI

Conference Coverage
Slideset

Analysis of the ARROS-1 study indicates durable responses and intracranial activity as well as manageable safety of zidesamtinib for patients with advanced ROS1+ NSCLC after prior ROS1 TKI treatment.

Released: November 17, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.